Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q4 CY2024, ...

McKesson Corporation (NYSE: MCK) has released its fiscal 2025 third quarter financial results. Results can be accessed on ...

Drug distributor McKesson missed estimates for third-quarter revenue on Wednesday, hurt by less-than-expected sales in its ...

Irving-based McKesson (NYSE: MCK) announced on Feb. 4 an agreement to buy an 80% controlling interest in New Providence, New ...

The stock's fall snapped a three-day winning streak.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...

Buying $100 In MCK: If an investor had bought $100 of MCK stock 20 years ago, it would be worth $1,621.13 today based on a ...

Q3 2025 Earnings Call Transcript February 5, 2025 Operator: Welcome to McKesson’s Third Quarter Fiscal 2025 Earnings ...

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors ...

With a positive outlook, McKesson raised its fiscal 2025 adjusted EPS guidance to a range of $32.55 to $32.95, indicating ...

Vitalone confirmed the company raised its adjusted EPS guidance to a range of $32.55 to $32.95 for fiscal 2025, representing 19%-20% year-over-year growth. Management raised full-year guidance for ...